Pfizer (NYSE:PFE) Stock Price Down 2.1% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) shares fell 2.1% during mid-day trading on Monday . The company traded as low as $25.48 and last traded at $25.6180. 34,959,832 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 41,525,152 shares. The stock had previously closed at $26.18.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s cancer pipeline is getting renewed attention after ASCO 2026 data showed strong late-stage results for its BRAFTOVI combination in metastatic colorectal cancer and TALZENNA combination in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Pfizer also announced a broad global oncology partnership with Innovent Biologics covering up to 12 early-stage programs, which could expand its cancer pipeline and support future revenue growth. Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?
• Positive Sentiment: Foundation Medicine received FDA approvals for companion diagnostics tied to Pfizer’s TALZENNA regimen, improving the commercial setup for one of Pfizer’s oncology assets. US FDA Approves FoundationOne CDx and FoundationOne Liquid CDx as Companion Diagnostics for TALZENNA
• Neutral Sentiment: Several analyst and commentary pieces were constructive on Pfizer’s valuation and dividend appeal, but also noted that investors may need patience before the stock’s fundamentals fully re-rate. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?
• Neutral Sentiment: Other recent coverage said Pfizer’s obesity and oncology pipeline could make 2026 a catalyst-rich year, while Jefferies reaffirmed its Buy rating. Pfizer’s Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Negative Sentiment: Some articles continue to emphasize Pfizer’s patent-cliff overhang and slower return profile versus peers, which may temper upside until newer drugs gain more traction. Meet the Biotech Stock That’s Trouncing Lilly, Merck, and Pfizer in 2026

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Guggenheim raised their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Barclays began coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Finally, CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Down 0.3%

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $145.62 billion, a P/E ratio of 19.50 and a beta of 0.34. The stock has a fifty day moving average price of $26.73 and a two-hundred day moving average price of $26.30.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is 131.30%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of the business. Evolution Wealth Management Inc. lifted its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Horizon Financial Services LLC increased its position in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership bought a new stake in Pfizer in the fourth quarter valued at $28,000. Finally, HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.